1. Petta, I., Lievens, S., Libert, C., Tavernier, J. & De Bosscher, K. Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics. Mol. Ther. J. Am. Soc. Gene Ther. 24, 707–718 (2016).
2. Binz, H. K., Amstutz, P. & Plückthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257–1268 (2005).
3. Crook, Z. R., Nairn, N. W. & Olson, J. M. Miniproteins as a Powerful Modality in Drug Development. Trends Biochem. Sci. 45, 332–346 (2020).
4. Blagg, J. & Workman, P. Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. Cancer Cell 32, 9–25 (2017).
5. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008).
6. Barthelemy, P. A. et al. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283, 3639–3654 (2008).
7. Holliger, P. & Hudson, P. J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126–1136 (2005).
8. Chen, W., Zhu, Z., Feng, Y., Xiao, X. & Dimitrov, D. S. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J. Mol. Biol. 382, 779–789 (2008).
9. Ma, X., Barthelemy, P. A., Rouge, L., Wiesmann, C. & Sidhu, S. S. Design of synthetic autonomous VH domain libraries and structural analysis of a VH domain bound to vascular endothelial growth factor. J. Mol. Biol. 425, 2247–2259 (2013).
10. Cornvik, T. et al. Colony filtration blot: a new screening method for soluble protein expression in Escherichia coli. Nat. Methods 2, 507–509 (2005).
11. Asial, I. et al. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nat. Commun. 4, 2901 (2013).
12. Bhat, M. et al. Targeting the translation machinery in cancer. Nat. Rev. Drug Discov. 14, 261–278 (2015).
13. Boussemart, L. et al. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature 513, 105–109 (2014).
14. Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C. & Vagner, S. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 21–25 (2017).
15. Zindy, P. et al. Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res. 71, 4068–4073 (2011).
16. Marcotrigiano, J., Gingras, A. C., Sonenberg, N. & Burley, S. K. Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G. Mol. Cell 3, 707–716 (1999).
17. Grüner, S. et al. The Structures of eIF4E-eIF4G Complexes Reveal an Extended Interface to Regulate Translation Initiation. Mol. Cell 64, 467–479 (2016).
18. Peter, D. et al. Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. Mol. Cell 57, 1074–1087 (2015).
19. Gingras, A. C. et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852–2864 (2001).
20. Frosi, Y., Usher, R., Lian, D. T. G., Lane, D. P. & Brown, C. J. Monitoring flux in signalling pathways through measurements of 4EBP1-mediated eIF4F complex assembly. BMC Biol. 17, 40 (2019).
21. Shveygert, M., Kaiser, C., Bradrick, S. S. & Gromeier, M. Regulation of Eukaryotic Initiation Factor 4E (eIF4E) Phosphorylation by Mitogen-Activated Protein Kinase Occurs through Modulation of Mnk1-eIF4G Interaction. Mol. Cell. Biol. 30, 5160–5167 (2010).
22. Averous, J., Fonseca, B. D. & Proud, C. G. Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27, 1106–1113 (2008).
23. Culjkovic, B., Topisirovic, I. & Borden, K. L. Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6, 65–69 (2007).
24. Mamane, Y. et al. eIF4E--from translation to transformation. Oncogene 23, 3172–3179 (2004).
25. Wendel, H.-G. et al. Dissecting eIF4E action in tumorigenesis. Genes Dev. 21, 3232–3237 (2007).
26. Polunovsky, V. A. et al. Translational control of the antiapoptotic function of Ras. J. Biol. Chem. 275, 24776–24780 (2000).
27. Li, S. et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell. Biol. 22, 2853–2861 (2002).
28. Li, S. et al. Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J. Biol. Chem. 279, 21312–21317 (2004).
29. Cerezo, M. et al. Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. Nat. Med. 24, 1877–1886 (2018).
30. Feldman, M. E. et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
31. Gani, O. A. B. S. M. & Engh, R. A. Protein kinase inhibition of clinically important staurosporine analogues. Nat. Prod. Rep. 27, 489–498 (2010).
32. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691–699 (2008).
33. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948–953 (1996).
34. Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997).
35. Moellering, R. E. et al. Direct inhibition of the NOTCH transcription factor complex. Nature 462, 182–188 (2009).
36. Dazert, E. & Hall, M. N. mTOR signaling in disease. Curr. Opin. Cell Biol. 23, 744–755 (2011).
37. Wang, X. et al. Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. EMBO J. 20, 4370–4379 (2001).
38. Moerke, N. J. et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell 128, 257–267 (2007).